Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Roberta Rondena"'
Autor:
Roberta Rondena, Fernando Gaion, Dino Amadori, Carla Ripamonti, Barbara Alessi, Lorenzo Gianni, Gabriella Farina, Daniele Santini, Paola Bogani, Toni Ibrahim, Francesco Bertoldo, Massimo Aglietta
Publikováno v:
The Lancet Oncology. 14:663-670
Zoledronic acid reduces skeletal-related events in patients with breast cancer, but concerns have been raised about prolonged monthly administration. We assessed the efficacy and safety of a reduced dosing frequency of zoledronic acid in women treate
Autor:
Francesco Bertoldo, Laura Mercatali, Fernando Gaion, Gabriella Farina, Barbara Alessi, Paola Bogani, Toni Ibrahim, Daniele Santini, Roberta Rondena, Massimo Aglietta, Dino Amadori, Lorenzo Gianni, Oriana Nanni, Carla Ripamonti
Publikováno v:
The Lancet Oncology. 14:e388-e390
Publikováno v:
Tetrahedron. 51:9985-9994
Reaction of oxazolones 4 with triphcnylvinylphosphonium bromidc 3 afforded, through a Michael addition, the α-aminocstcrs 7 or acids 8 functionalized with a triphcnylphosphonium group. Compounds 7 and 8 were transformed in good yields in the corresp
Autor:
Roberta Rondena, Vito Lorusso, Vincenza Vinaccia, Francesco Giotta, Giacomo Cartenì, Roberto Bordonaro, Dino Amadori, Simona Scalone
Publikováno v:
The oncologist. 11(7)
Purpose. This study evaluated the efficacy and safety of zoledronic acid in breast cancer patients with newly diagnosed bone metastases. Materials and Methods. Patients diagnosed with bone metastases ≤ 6 weeks prior to first visit were enrolled. Zo
Publikováno v:
Water Resources Research. 41
[1] The structure and function of vegetation regulate fluxes across the biosphere-atmosphere interface with large effects in water-limited ecosystems. Vegetation dynamics are often neglected in hydrological modeling except for simple prescriptions of
Autor:
Dino Amadori, Fernando Gaion, Francesco Bertoldo, Roberta Rondena, Massimo Aglietta, Daniele Santini, Gabriella Farina, Barbara Alessi, Paola Bogani, Toni Ibrahim, Carla Ripamonti, Lorenzo Gianni
Publikováno v:
Journal of Clinical Oncology. 30:9005-9005
9005 Background: ZOL (4 mg q 4 wk) is an established therapy for reducing the risk of debilitating skeletal-related events (SREs) in patients (pts) with bone metastases (mets) from BC. As BC treatments continue to improve pt survival, long-term SRE-r